India’s Eris launches $14 monthly generic Ozempic shot, among cheapest globally

India’s Eris Lifesciences on Friday launched one of the most affordable versions of Ozempic so far, with the lowest dosage of generic semaglutide starting at 1,290 rupees ($13.8) per month.

Launch under the brand Sundae in India for diabetes, with lowest dose of a Sundae vial, at 2 mg.

Natco Pharma, Eris’ partner for the semaglutide launch, priced its lowest 2 mg dose at 1,290 rupees a month.

Eris also plans to launch a pen device version of Sundae in April, in three dosages. The lowest 2 mg dose will cost 4,000 rupees per month and the highest 8 mg dose 4,500 rupees per month.

Eris is among dozens of Indian drugmakers that are launching generic semaglutide as Danish drugmaker Novo Nordisk’s semaglutide patent is set to expire on March 20.

Novo Nordisk patent expiry opens door to cheaper weight-loss drugs in India

Larger peer Dr Reddy’s is expected to launch on Saturday.

Indian generic drugmakers, known globally for producing low-cost medicines, are expected to price their generics at discounts of at least 50% to 60%.

On a monthly basis, Sundae’s lowest dose is 88% cheaper than that of Novo’s Wegovy and 91% cheaper than the lowest dose of U.S. drugmaker Eli Lilly’s Mounjaro.